| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | IC-87114 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | JQ-1:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | VER-155008 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | SB 505124 | GDSC1000 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |